Is tesamorelin FDA-approved? Egrifta WR, compounding and evidence
As of October 15, 2026, tesamorelin's FDA approval covers one use: Egrifta WR, a once-daily 1.28 mg injection that reduces excess abdominal fat in adults with HIV and lipodystrophy, and its label states that it is not indicated for weight-loss management. Any other use is off-label, and compounded tesamorelin is not an FDA-approved product. On August 24, 2026, FDA named tesamorelin as an unapproved new drug in warning letters to five 'research use only' peptide sellers. WADA prohibits it in sport as a growth-hormone-releasing hormone analogue.
Status at a glance
| Check | Status as of October 15, 2026 | Source · read date |
|---|---|---|
| FDA approval | Approved as EGRIFTA WR (BLA 022505; initial U.S. approval 2010; deemed a BLA on March 23, 2020) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. “Not indicated for weight loss management.” | FDA · read October 15, 2026; Drugs@FDA |
| 503A interim category | Not in FDA’s interim 503A categories (categories PDF updated May 14, 2026). Compounded tesamorelin is not the approved product. | FDA · read October 15, 2026 |
| FDA advisory committee (PCAC) | None found for 2025–2026. | FDA · read October 15, 2026 |
| WADA 2026 Prohibited List | S2.2.4, named as a GHRH analogue. Prohibited at all times. | World Anti-Doping Agency · read October 15, 2026 |
| FDA warning letters, 2026 | Named as an unapproved new drug in all five August 24, 2026 letters to research-use-only sellers. | FDA letter 735063 and four others · read October 15, 2026 |
| WADA 2027 list | Entry unchanged on the 2027 list (approved September 10, published September 21, in force January 1, 2027). | World Anti-Doping Agency · read October 15, 2026 |
What the Egrifta WR label says
The current label (supplement approved March 25, 2025) reads: “EGRIFTA WR is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.” Under limitations of use it says: “Not indicated for weight loss management.” The labelled dose is “1.28 mg (0.16 mL of the reconstituted solution) injected subcutaneously once daily.” The label also states: “EGRIFTA WR and EGRIFTA SV are not substitutable” (FDA label).
So tesamorelin is the one growth-hormone peptide on this site with a current approval — but for one population and one outcome. Using it for general fat loss, anti-ageing or performance is off-label.
Human evidence
FDA approved tesamorelin on the basis of clinical trials in adults with HIV and lipodystrophy, which is the strongest human evidence any peptide on this site has. We have not re-read those trials for this update, so we do not quote their results here; the label is the authoritative summary. We did not find comparable trials in people without HIV-associated lipodystrophy, and approval for one condition is not evidence for another.
Animal and laboratory evidence
Animal data on tesamorelin matter less than for the other peptides here, because human trial data exist for the approved use. For unapproved uses, animal results are not a substitute for trials in people.
Risks
The Egrifta WR label lists contraindications, warnings and adverse reactions; read it with your prescriber before starting (label PDF). Compounded tesamorelin carries additional uncertainty because no regulator reviewed that specific product, and products from research-use websites carry the most: FDA named tesamorelin in all five of its August 2026 letters to such sellers.
Legal sourcing: who can supply it
For the approved use, the route is a prescription for Egrifta WR filled by a pharmacy. For anything else, ask the clinic whether you are getting Egrifta WR or a compounded preparation, which pharmacy makes it and on what legal basis — FDA’s interim categories do not list tesamorelin. See how to verify a provider.
The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.
October 2026: what changed
- April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
- July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
- October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.
For tesamorelin: the August 24 letters are the main 2026 development, showing FDA treats research-use tesamorelin, including tesamorelin-ipamorelin blends, as unapproved new drugs. Its approval did not change. See research vs prescription peptides.
Frequently asked questions
Is tesamorelin FDA-approved?
As of October 15, 2026, tesamorelin's FDA approval covers one use: Egrifta WR, a once-daily 1.28 mg injection that reduces excess abdominal fat in adults with HIV and lipodystrophy, and its label states that it is not indicated for weight-loss management. Any other use is off-label, and compounded tesamorelin is not an FDA-approved product. On August 24, 2026, FDA named tesamorelin as an unapproved new drug in warning letters to five 'research use only' peptide sellers. WADA prohibits it in sport as a growth-hormone-releasing hormone analogue.
Is tesamorelin approved for weight loss?
No. The Egrifta WR label states it is “not indicated for weight loss management.” Its only approved use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Using it for general fat loss is off-label.
Is compounded tesamorelin the same as Egrifta WR?
No. A compounded preparation is not the FDA-approved product, and the FDA does not review its quality, safety or effectiveness before you receive it. The label also says EGRIFTA WR and EGRIFTA SV are not substitutable, which shows how formulation-specific approval is.
Why did FDA send warning letters about tesamorelin?
On August 24, 2026, FDA warned five “research use only” peptide sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — that their tesamorelin products were unapproved new drugs. FDA said the research labels did not change that conclusion.
Is tesamorelin banned in sport?
Yes. WADA’s 2026 Prohibited List names tesamorelin under S2.2.4 as a growth-hormone-releasing hormone analogue, prohibited at all times. A prescription does not exempt an athlete; a therapeutic use exemption is a separate process.
New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).
Sources
- FDA — EGRIFTA WR (tesamorelin) prescribing information, supplement approved March 25, 2025 (read October 15, 2026)
- Drugs@FDA — application 022505 (tesamorelin) (read October 15, 2026)
- FDA — Interim policy categories for 503A and 503B bulk drug substances (PDF, updated May 14, 2026) (read October 15, 2026)
- World Anti-Doping Agency — Prohibited List (2026 list in force) (read October 15, 2026)
- FDA warning letter — Peptide Partners LLC, 735063 (August 24, 2026) (read October 15, 2026)
- FDA warning letter — Peak Performance Peptides, 735127 (August 24, 2026) (read October 15, 2026)
- FDA warning letter — Royal Peptides LLC, 734884 (August 24, 2026) (read October 15, 2026)
- FDA warning letter — NuScience Peptides LLC, 733652 (August 24, 2026) (read October 15, 2026)
- FDA warning letter — TXP Innovations LLC dba Tex Peptides, 735067 (August 24, 2026) (read October 15, 2026)
- OIRA (reginfo.gov) — Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94 (pending EO 12866 review) (read October 15, 2026)
- Reuters via Yahoo News — FDA takes step to change peptide compounding access (October 15, 2026) (read October 15, 2026)
- World Anti-Doping Agency — 2027 Prohibited List (published September 21, 2026; in force January 1, 2027) (read October 15, 2026)